单等位MEFV变异增加局灶节段性肾小球硬化风险
在Mass General Brigham生物样本库13万成员中,通过病理报告筛查识别319例FSGS或MCD患者,9.7%携带孟德尔变异,7.5%携带APOL1高风险基因型,二者肾衰竭风险分别增加3.1倍和6.5倍。意外发现6例FSGS患者携带单等位MEFV致病变异,均表现为塌陷性肾小球病和血栓性微血管病,并在外部队列中验证MEFV与激素抵抗型肾病综合征相关。
要点
- 成人NS中17.2%有明确遗传病因,均增加肾衰竭风险。
- 病理报告为继发性FSGS不应排除基因检测。
- 单等位MEFV致病变异可能是SRNS/FSGS新易感因素。
核心结论
- Mass General Brigham生物样本库中17.2%未选择性成人NS患者有明确遗传病因,与肾衰竭风险增加相关。
- 单等位MEFV致病变异可能是SRNS/FSGS的新型易感因素,即使无FMF临床表现。
研究设计与样本
- 在Mass General Brigham生物样本库13万成员中测试三种策略识别FSGS或MCD病例。
- 对具有外显子组测序数据的患者分析192个孟德尔基因的合成蛋白尿panel和APOL1肾脏风险变异。
- 在Genomics England 100,000 Genome Project和全球NS病例对照队列中验证新基因-FSGS关联。
主要发现
- 319例MGBB参与者有FSGS或MCD及外显子组测序数据,病理报告审查是最准确的筛查策略。
- 31例(9.7%)携带孟德尔变异,24例(7.5%)携带APOL1高风险基因型。
- 有肾活检报告的遗传性NS中61%被分类为继发性FSGS。
- 孟德尔变异和APOL1患者发生肾衰竭的比值比分别为3.1(1.1-8.7)和6.5(1.3-32.3)。
- 6例MGBB FSGS患者携带单等位MEFV致病变异,均有塌陷性肾小球病和血栓性微血管病特征;100KG中8例未解 glomerular disease病例携带单等位MEFV致病变异;病例对照研究显示致病或可能致病MEFV等位基因个体SRNS比值比增加3.8(P=7.8×10-5)。
临床怎么用
- 对NS患者应积极进行基因检测,即使病理报告为继发性FSGS。
- 单等位MEFV致病变异可作为SRNS/FSGS的潜在遗传筛查靶点,尤其伴塌陷性肾小球病或TMA时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Health system-based biobanks with genetic data provide a unique opportunity for nephrotic syndrome (NS) genomic discovery. This is predicated on finding cases in the electronic health record. METHODS: We tested three strategies to identify focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) cases in the 130,000 members of Mass General Brigham Biobank (MGBB). We analyzed a "synthetic proteinuria panel" of 192 Mendelian genes and the APOL1 kidney risk variants in those with exome sequencing (ES). We studied the associations between patients with Mendelian variants (MV), APOL1-HR genotype (APOL1) and outcomes. Validation of a novel gene-FSGS association was done in the Genomics England 100,000 Genome Project (100KG) and a global NS case-control cohort. RESULTS: 319 MGBB participants had FSGS or MCD and ES data; reviewing pathology reports was the most accurate screening strategy. 31 (9.7%) of patients had MV and 24 (7.5%) had APOL1. 61% of genetic NS with a kidney biopsy report were classified as secondary FSGS. MV and APOL1 patients had a 3.1 (1.1-8.7) and 6.5 (1.3-32.3) increased odds of developing kidney failure, respectively. Unexpectedly, monoallelic pathogenic variants in MEFV (Mendelian gene for Familial Mediterranean Fever [FMF]) were found in 6 MGBB participants with FSGS, all of whom had features of collapsing glomerulopathy and thrombotic microangiopathy. 8 glomerular disease cases in the 100KG, unsolved via genome sequencing, had monoallelic pathogenic MEFV variants. Finally, a case-control study found a 3.8 increased odds of SRNS in individuals with pathogenic or likely pathogenic MEFV alleles (P = 7.8 × 10-5). CONCLUSIONS: 17.2% of unselected adults with NS in the MGBB had a well-established genetic form, each associated with an increased risk of kidney failure. A biopsy read of secondary FSGS should not be used to rule out testing for genetic disease. Monoallelic pathogenic variants in MEFV may be a novel and underappreciated cause or susceptibility factor for SRNS/FSGS with distinct histologic features, even in the absence of clinical FMF.
引用
- Wongboonsin J, Gibson KM, Ke J, et al. Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis. Kidney Int. 2025. PMID: 41453490. doi:10.1016/j.kint.2025.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。